How Can We Tailor Antifungal Therapy?
|
|
- Julius Bell
- 5 years ago
- Views:
Transcription
1 How Can We Tailor Antifungal Therapy? Russell Lewis Infections Diseases Unit Department of Medical Sciences and Surgery S.Orsola Malpighi Hospital University of Bologna
2 Most Common Infectious Diagnosis in Hematology Patients at S Orsola-Malpighi Hospital, (n=1,712 episodes) Group % of cases No pathogen identified 45.9 Bacterial 41.9 Aspergillus (GM diagnosis-probable) 2.2 Invasive mold (possible) 1.9 Aspergillus + bacteria (GM diagnosis probable) 1.9 Mold proven 1.4 Invasive mold (possible) + bacteria 1.3 Bacterial + Yeast 0.8 CMV 0.6 Yeast 0.5 Non-CMV viral infection %
3 Crude Mortality of Invasive Fungal Infections in Hematology Patients, S Orsola Malpighi Candida, n=20 Survival probability (%) % survival at 6 weeks* Proven or probable mold n=105 0 p= Days After Admission Includes mixed infections * 6-Week survival reported with voriconazole monotherapy=72.5% (Marr et al. ECCMID 2012)
4 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who (or who does not) need antifungal therapy? What should be our guiding principles of antifungal therapy for invasive mold disease? Can we avoid chronic toxicities of antifungals?
5 Guidelines provide little guidance of who really needs antifungal therapy High-risk High-risk for molds Consider prophylaxis Neutropenia > 10 days, comorbidities, persistent fever Remission-induction AML/MDS Allogeneic HSCT Freifeld et al. Clin Infect Dis 2011;52:e56-e93.
6 The incidence of aspergillosis varies considerably from one transplant center to the next 12-Month Cumulative Incidence (# aspergillus cases/# allogeneic HSCT transplants) TransNet Database Cumulative Incidence Study site Morgan et al. Medical Mycology 2005;S49-58.
7 Clinical trials for invasive fungal infections may not reflect the patients you are treating Clinical trial (inclusion/exclusion criteria) EORTC/MSG Definitions Your institution? Goal: Homogeneous population, that gives drug best chance to work Greater diagnostic uncertainty, multiple comorbidities, prior treatments, co-infections, drug interactions, contraindications, terminal stages of underlying disease
8 Risk of invasive aspergillosis based on primary host factor INTERMEDIATE RISK LOW RISK HIGH RISK Chronic granulomatous disease Allogeneic HSCT with graft versus host disease Myelodysplastic syndrome treated with remission-induction chemotherapy Acute myeloblastic leukemia treated with remission-induction chemotherapy Lung or heart transplantation Small-bowel transplantation Liver transplantation Allogeneic HSCT without graft versus host disease Acute myeloblastic leukemia during consolidation phase Acute lymphoblastic leukemia Heart transplantation Chronic lymphocytic leukemia Myelodysplastic syndrome Multiple myeloma COPD with acute exacerbation AIDS Non-Hodgkin s lymphoma Autologous HSCT Kidney transplantation Solid tumor Autoimmune disorder Herbrecht et al. Ann NY Acad Sci 2012;1272:23-30.
9 Risk Factors Influencing Host Condition INNATE IMMUNE STATUS UNDERLYING CONDITION Toll-like receptor polymorphism C-type lectin receptor polymorphism Mannose binding lectin polymorphism Plasminogen polymorphism Other polymorphisms? PRIMARY HOST FACTOR Neutropenia Progressive cancer Graft versus host disease Anticancer chemotherapy Corticosteroids Anti-T-cell antibodies Hematological Malignancy Allogeneic HSCT SOT Climate Solid tumor Construction work Other immune disorder Place of residence Tobacco or cannabis use Contaminated food or spices Pets, plotted plants and gardening No HEPA filtration during hospitalizations ENVIRONMENTAL FACTORS Diabetes Iron overload Trauma, burns Renal impairment Metabolic acidosis Prior respiratory disease OTHER FACTORS Herbrecht et al. Ann NY Acad Sci 2012;1272:23-30.
10 Retrospective Review-Patient Characteristics Characteristics Hospitalization n=1,709 episodes (%)* Median age (range) 52 (15-84) Sex, male 1,013 (59) Median no. of hospitalizations (range) 2 (1-12) Underlying malignancy (%) AML/MDS 527 (31) ALL 176 (10) CML 50 (3) CLL 19 (1) Lymphoma 490 (29) MM/ amyloidosis 418 (24) Aplastic anemia 13 (0.8) Non-neoplastic 16 (0.9) Allogeneic HSCT 203 (12) Autologous HSCT 584 (34) Stanzani et al. Submitted *At least 5 days of hospitalization
11 Risk Factors (n=12 of 17) Associated with Invasive Mold Disease by Univariate Analysis Risk factor No IMD (%) n=1650 IMD (%) n=59 P value At-risk profession (spore exposure) 168 (10) 10 (17) 0.05 Prior invasive mold disease 31 (2) 7 (12) < Corticosteroids 312 (19) 16 (27) 0.06 Diabetes 156 (9) 10 (17) 0.03 High-risk malignancy 555 (34) 37 (63) < Uncontrolled malignancy 755 (46) 47 (80) < High-risk chemotherapy 512 (31) 37 (63) < Neutropenia > 10 days 596 (36) 48 (81) < Lymphocytopenia (< 50/mm 3 ) 415 (25) 31 (53) < Acute GVHD, grade II-IV 47 (3) 5 (8) 0.02 Mucositis, Grade III-IV 206 (12) 14 (24) Admitted to a room without HEPA filtration 587 (36) 29 (49) 0.01 Stanzani et al. Submitted
12 Risk factors Independently Associated Invasive Mold Disease In Multivariate Logistic Regression Variable Prolonged neutropenia IMD Incidence (%) β-coefficient Wald χ 2 P value 596 (41) < Previous IMD 31 (9) < Malignancy status 755 (50) < Lymphocytopenia 415 (31) Hazard Ratio (95% CI) 5.60 ( ) 5.55 ( ) 4.64 ( ) 2.45 ( ) Points Risk score (0-13 points) Stanzani et al. Submitted
13 A weighted risk score can screen-out patients unlikely to develop invasive mold disease Sensitivity aroc=0.84 (95% CI ) P< Specificity Percent Criterion value Specificity Sensitivity Risk Score Study Cohort Sens (95% CI) Spec (95% CI) PPV (95% CI) NPV (95% CI) (n=1,709) 0.86 ( ) 0.74 ( ) 0.10 ( ) 0.99 (0.99-1) Stanzani et al. Submitted
14 Risk Score Validation n=1,746 episodes (855 patients) % Proven or Probable IMD Score =1,709 episodes =1,746 episodes Study Cohort aroc Sens (95% CI) Spec (95% CI) PPV (95% CI) NPV (95% CI) (n=1,746) 0.76 ( ) 0.69 ( ) 0.76 ( ) 0.10 ( ) 0.98 ( ) Stanzani et al. Submitted
15 Consistent NPV Across Various Primary Host Factors Validation cohort Primary host factor (Risk score) AML (remission-induction), n=141 (median=7) AML (consolidation/salvage), n=285 (median=4) Lymphoma, n=390 (median=3) Allogeneic HSCT, n=227 (median=6) Autologous HSCT, n=344 (median=0) IMD Prevalence aroc Sensitivity Specificity PPV NPV 5.7% ( ) 2.1% ( ) 2.1% ( ) 11% ( ) 0.8% ( ) 0.28 ( ) 0.05 ( ) 0.93 ( ) 0.32 ( ) 0.06 ( ) 0.06 ( ) 0.05 ( ) 0.20 ( ) 0.22 ( ) ( ) 0.95 ( ) 0.99 ( ) 0.99 ( ) 0.93 ( ) 1.0 ( ) Stanzani et al. Submitted
16 What is the impact posaconazole prophylaxis? under utilized? Score < 6 Score > 6 10 P= n=448 % Cumulative Invasive Mold Disease unnecessary? n=92 n= n=108 ARR 6.1% P=0.008* 0 Pos No Pos 0 Pos No Pos *Posaconazole vs. itraconazole/fluconazole trial. ARR 6.0% Cornely et al., N Eng J Med 2007;356: Stanzani et al. Submitted
17 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who needs (or does not need) antifungal therapy? Clinical risk score screening seems feasible as first step towards risk stratification What should be our guiding principles of antifungal therapy for invasive mold disease? Can we avoid chronic toxicities of antifungals?
18 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who needs (or does not need) antifungal therapy? Clinical risk score screening seems feasible as first step towards risk stratification What should be our guiding principles of antifungal therapy for invasive mold disease? Can we avoid chronic toxicities of antifungals?
19 Pathogenesis of invasive molds and timing of antifungal treatment Radiographic signs inhaled conidia reach distal airspace macrophages and PMN block replication sub-clinical fungal proliferation disease detectable by high resolution CT extensive necrosis limits drug delivery dissemination and death Prophylaxis Large numbers of patients unnecessarily exposed to antifungals Preemptive requires sensitive surrogate markers (diagnostics) galactomannan? beta-glucan? PCR? Empiric Large numbers of patients unnecessarily treated, antifungals are administered late in the course of infection Pathogen-directed late in treatment course when fungal burden is high Risk of inappropriate therapy
20 Factors to consider when selecting antifungal therapy SPECTRUM PK PREDICTABILITY? SAFETY CONVIENENCE Lipid AMB Lipid AMB Fluconazole Fluconazole Posaconazole Echinocandin Echinocandin Voriconazole Voriconazole Fluconazole Posaconazole Posaconazole Echinocandin Voriconazole (IV) Voriconazole Echinocandin Fluconazole Voriconazole (PO) Lipid AMB Lipid AMB Posaconazole Chronic phase of treatment Acute phase of treatment Sometimes the best drug is not a single drug? The answer is always individualized to the patient, dynamic risks Does TDM improve PK confidence, equally important in acute and chronic phases?
21 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who needs (or does not need) antifungal therapy? Clinical risk score screening seems feasible as first step towards risk stratification What should be our guiding principles of antifungal therapy for invasive mold disease? Spectrum, activity and PK predictability in the acute treatment phase; then more balance towards safety and convenience in the chronic treatment phase Can we avoid chronic toxicities of antifungals?
22 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who needs (or does not need) antifungal therapy? Clinical risk score screening seems feasible as first step towards risk stratification What should be our guiding principles of antifungal therapy for invasive mold disease? Spectrum, activity and PK predictability in the acute treatment phase; then more balance towards safety and convenience in the chronic treatment phase Can we avoid chronic toxicities of antifungals?
23 Common Antifungal Toxicities Hepatic Renal toxicity CNS Photopsia Cutaneous?? All azoles Amphotericin B 5FC Echinocandins Amphotericin B; Cyclodextrans possibly toxic (IV voriconazole) Hyponatremia (azoles) Voriconazole Voriconazole Rash (all antifungals) Phototoxicity /malignancy? (voriconazole) GI Cardiac Infusion reactions Bone marrow suppression Itraconazole Posaconazole 5FC Cardiomyopathy (itraconazole, voriconazole, posaconazole) QTc prolongation (All azoles, especially with drug interactions) Amphotericin B Echinocandins Flucytosine Amphotericin B (anemia associated with decreased epoetin production)
24 Severe phototoxicity/ squamous cell carcinoma with voriconazole Risk factors Voriconazole treatment > 6-9 months Older patients Fair skin High sun exposures Profound immunosuppression Cowen et al. J Acad Dermatol 2010;62: Clancy & Nguyen. Curr Infect Dis Report 2011;13:
25 Severe phototoxicity with voriconazole- Not necessarily an idiosyncratic reaction? No absorbance at UVA or UVB spectrum N-Oxide Metabolite Absorbance in UVA and UVB range ( nm), possibly acting as a chromophore for phototoxicity Strongly influenced by CYP2C19 genotype, enterohepatic circulation 4-hydroxy metabolite No absorbance in UVA and UVB range Scholz et al. B J Clin Pharm 2009;68: Murayama et al. Biochem Pharmacol 2007;73:1-7.
26 Drug Interactions with Triazole Antifungals Substrate Voriconazole Inhibitor Fluconazole Itraconazole Substrate Voriconazole Inhibitor Fluconazole Voriconazole Voriconazole 2C9 2C19 ENZYME SYSTEM 3A4 P-GP transporter Substrate Itraconazole Voriconazole Inhibitor Fluconazole Itraconazole Voriconazole Posaconazole Substrate Posaconazole Voriconazole Inhibitor Itraconazole Posaconazole Figure: P. Donnelly. Brüggemann et al. Clin Infec Dis 2009:48:
27 Toxicodynamics of itraconazole: Implications for therapeutic drug monitoring n=216 chronically treated patients, 99 (46%) developing AE: Fluid retention (21%) 93% peripheral edema CHF symptoms GI intolerance (21%) 17.1 mg/l (bioassay) Lestner et al. Clin Infect Dis 2009;49: Is posaconazole similar?
28 This presentation focuses on general strategies to maximize the efficacy and safety of antifungal therapy Can we better target who needs (or does not need) antifungal therapy? Clinical risk score screening seems feasible as first step towards risk stratification What should be our guiding principles of antifungal therapy for invasive mold disease? Spectrum, activity and PK predictability in the acute treatment phase; then more balance towards safety and convenience in the chronic treatment phase Can we avoid chronic toxicities of antifungals? Avoidance/ management may be improved with TDM
29 I would like to acknowledge colleagues at S Orsola Malpighi Hospital Institute of Hematology, "Lorenzo e Ariosto Seràgnoli Marta Stanzani, M.D., Ph.D. Nicola Vianelli, M.D. Riccardo Ragionieri (database) Physicians, nurses, fellows involved in data collection Infectious Diseases Unit Pierluigi Viale, M.D., Ph.D.
Tailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna
Tailored Antifungal Modification in Breakthrough Mold Infections Russell E. Lewis University of Bologna 45 year-old patient with AML and documented pulmonary aspergillosis during remissioninduction chemotherapy
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationAspergillosis in Pediatric Patients
Aspergillosis in Pediatric Patients Emmanuel Roilides, MD, PhD, FIDSA, FAAM 3rd Department of Pediatrics Aristotle University School of Medicine Thessaloniki, Greece 1 Transparency disclosures Independent
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationCombination Antifungal Therapy for Invasive Aspergillosis
MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationA CME/CE-CERTIFIED WEBCOURSE. Program Transcript
A CME/CE-CERTIFIED WEBCOURSE Program Transcript Program Steering Committee/Faculty: ELIAS ANAISSIE, MD Medical Director, CTI Clinical Trial and Consulting Services Associate, Metropolitan Infectious Diseases
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationVoriconazole in Prevention and Treatment of Febrile Neutropenia
2016 jpc.tums.ac.ir Voriconazole in Prevention and Treatment of Febrile Neutropenia Hamidreza Taghva Masoumi 1, Molouk Hadjibabaie 1,2, Kheirollah Gholami 1,2, Maryam Shahrokhi 1* 1 Clinical Pharmacy Department,
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationInvasive Aspergillosis in India: Unique Challenges. Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai
Invasive Aspergillosis in India: Unique Challenges Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai Aspergillus Challenges Capable of surviving & thriving in all the diverse environmental
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationby author The Interaction Between Influenza and Aspergillus Carolina Garcia-Vidal Infectious Diseases Department Hospital Clínic Barcelona
The Interaction Between Influenza and Aspergillus Carolina Garcia-Vidal Infectious Diseases Department Hospital Clínic Barcelona Influenza-associated aspergillosis-eccmid 2018 23 April 2018 Relationship
More informationPAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationAbstract. Introduction. Editor: M. Paul
ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation
More informationAntifungal prophylaxis: Whom, what and when
Antifungal prophylaxis: Whom, what and when Professor Yee-Chun Chen Professor of Medicine National Taiwan University Hospital and College of Medicine; Investigator, National Institute of Infectious Diseases
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion Y.-Q. Sun, L.-P. Xu,
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationControversies in management: prophylaxis or diagnostics
5 th Advances Against Aspergillosis Controversies in management: prophylaxis or diagnostics Caveats in the use of biological markers for early diagnosis Drosos E. Karageorgopoulos, MD Researcher, Alfa
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationMonitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography
Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography M. P. Domingo, M. Vidal, J. Pardo, A. Rezusta, L. Roc,
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationFungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy
Fungal infections Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia Epidemiology Diagnostic approach Prevention strategies Monitoring of IFDs in
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationposaconazole, or prayers
Antifungal therapy: Polyenes, posaconazole, or prayers Michael Kleinberg, MD, PhD Associate Professor of Medicine Head, Infectious Diseases Section Marlene and Stewart Greenebaum Cancer Center University
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationPentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients with intensive chemotherapy
Published Ahead of Print on June 7, 2018, as doi:10.3324/haematol.2018.195453. Copyright 2018 Ferrata Storti Foundation. Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology oncology patients: a retrospective cohort study Hsiang-Chi
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationInvasive Aspergillosis in Steroid-Treated Patients
Invasive Aspergillosis in Steroid-Treated Patients Dimitrios P. Kontoyiannis, MD, ScD Professor of Medicine Department of Infectious Diseases Infection Control and Employee Health PMN damaging Aspergillus
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationComplications after HSCT. ICU Fellowship Training Radboudumc
Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationElements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationResearch priorities in medical mycology
Research priorities in medical mycology David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Agenda How many patients are there with serious
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationASPERGILLOSIS IN THE NON-NEUTROPENIC HOST
ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationRiposta immune versus stato immune
Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency
More information